Fig. 3.
BCL-2-overexpressing KB cells whose endogenous MCL-1 confers resistance to ABT-737. (a) Stable overexpression of BCL-2 in KB cells. (b) Reduction of MCL-1 expression in KB/BCL-2 cells by MCL-1 siRNA. (c) MCL-1 knockdown confers sensitivity to ABT-737 in KB/BCL-2 cells. KB/BCL-2 cells were transfected with human MCL-1 siRNA or luciferase (Luc) siRNA and plated into media containing 0.5 μM ABT-737. After 72, the percentage of cells incorporating annexin V FITC and propidium iodide was determined by flow cytometry.